期刊文献+

三阴性乳腺癌化疗方案的对比 被引量:5

三阴性乳腺癌化疗方案的对比
下载PDF
导出
摘要 探讨三阴性乳腺癌患者的临床病理特征及预后影响因素,对比其化疗方案疗效,从而找到一种更能很好地改善乳腺癌患者的病情,减少患者对化疗的不良反应,减轻病人的痛苦,降低复发率。 Exploring the clinical pathological features and the factors who influence the prognosis of people who have Triple Negative Breast Cancer.We use two chemotherapy regimens,so we will contrast the efficacy of the two regimens.Through this,we can find an effective way of improving the disease and reducing the side effects of patients with breast cancer.We should reduce the patients' suffering and the recurrence rate.
机构地区 大连市妇产医院
出处 《中外医疗》 2012年第3期8-9,共2页 China & Foreign Medical Treatment
关键词 乳腺癌 预后 化疗 Breast Cancer Prognosis Chemotherapy
  • 相关文献

参考文献8

二级参考文献16

  • 1陈廷祚.Gaojushen:a novel anti-cancer drug prepared from SEC superantigen[J].微生物学免疫学进展,2005,33(2):49-50. 被引量:3
  • 2陈廷祚.SEC口服液有效剂量判定依据和准则[J].微生物学免疫学进展,2005,33(2):51-58. 被引量:2
  • 3冯玉梅,李晓青,孙保存,曹旭晨,顾林,牛昀,郝希山.基于乳腺原发癌基因表达谱的预后分子分型研究[J].中华肿瘤杂志,2006,28(12):900-906. 被引量:3
  • 4Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Aead Sei U S A, 2001,98:10869-10874.
  • 5Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tmnours. Nature. 2000. 406,747-752.
  • 6Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology, 2005, 69:478-485.
  • 7Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression d luminal and basal cytokeratins in human breast carcinoma. J Pathol, 2004, 203:661-671.
  • 8van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol, 2002, 161:1991-1996.
  • 9Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 2003, 100:8418-8423.
  • 10Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 2006, 19:264-271.

共引文献67

同被引文献43

  • 1江泽飞,宋三泰.蒽环类化疗药物治疗乳腺癌的新动向[J].中华肿瘤杂志,2005,27(4):193-195. 被引量:27
  • 2林本耀.乳腺癌[M].北京:中国医药科技出版社,2006:156.
  • 3智慧,罗葆明,欧冰,冯霞,文艳玲.对乳腺弹性成像5分评分法的进一步探讨[J].中国超声医学杂志,2007,23(5):349-351. 被引量:34
  • 4孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1998.45.
  • 5Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (versionl. 1 ) [ J ]. Eur J Cancer, 2009,45 ( 3 ) : 228 - 247.
  • 6Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer : clinical features and pattems of recurrence[ J]. Clin Cancer Res ,2007,13 ( 15ptl ) :4429 - 4434.
  • 7Sirohi B, Arnedos M, Popat S, et al. Platinum-based chcmotheapy in triple-negative breast cancer [ J ]. Ann 0ncol,2008,19 ( 11 ) : 1847 - 1852.
  • 8Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin triple-negative breast cancer [ J]. J Clin Oncol, 2010,28 (7) : 1145 - 1153.
  • 9GOLDIE J H, COLDMAN A J. A mathematical model for r- elating the drug sensitivity of tumors to their spontaneous mutation rate [J]. CancerTreat Rep, 1979,63 ( 11-12 ): 1 727-1 733.
  • 10GUNDUZ, FISHER B, SAFFER E A. Effect of surgical r- emoval on the growth and kinetics of residual tumor [J ]. CaneerRes, 1979,39( 10):3 861 -3 865.

引证文献5

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部